Section Arrow
Quote
PTHS.NYSE-M
- Pelthos Therapeutics Inc
Quotes are at least 15-min delayed:2025/11/16 02:41 EST
Regular Hours
Last
 33.61
-1.07 (-3.09%)
Day High 
35 
Prev. Close
34.68 
1-M High
37.5 
Volume 
42.07K 
Bid
24.2
Ask
37.56
Day Low
28.495 
Open
33 
1-M Low
22.48 
Market Cap 
106.18M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 34.99 
20-SMA 33.54 
50-SMA 31.36 
52-W High 54.29 
52-W Low 4.5 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-14.66/-1.55
Enterprise Value
106.18M
Balance Sheet
Book Value Per Share
-2.12
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 02:41 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.